Despite their exceptional anti-inflammatory properties, the use of systemic glucocorticoids (GCs) for the treatment of rheumatoid arthritis (RA) remains controversial due to the potential side effects, particularly their role in elevating patients’ risk of cardiovascular (CV) events. A po

Chronic in ammation caused by RA is hypothesized to contribute to the development of PD later in life. Autoimmunity has long been suspected to have a role in the initiation and amplication of brain in ammation via the activation of microglia and monocytes. Genomic analyses have also revealed that PD is pleiotropic with various autoimmune diseases. However, previous investigations have shown con icting results.

1. Kang J, et al. Rheumatoid Arthritis and Risk of Parkinson Disease in Korea. JAMA Neurol. 2023:e230932.

Based on inputs from a global task force on recent systematic literaturereviews (SLRs) regarding rheumatoid arthritis (RA), experts from theEuropean Alliance of Associations for Rheumatology (EULAR) updatedrecommendations for the RA management.1 The previous guidelineswere updated in 2019.2 One main

Dupilumab, a monoclonal antibody previously indicated for the treatment of atopic dermatitis and asthma, has been recently approved by the United States (US) Food and Drug Administration (FDA) for treating eosinophilic esophagitis (EoE), a chronic, inflammatory disease in which the build-up of a typ

Over time, it has become clear that rheumatoid arthritis (RA) patients are at increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE).¹ EULAR President Professor Iain McInnes from The University of